Adjuvant therapy for colon cancer

Surgical Oncology Clinics of North America

Volumn 19, Issue 4, 2010, Pages 819-827

  Saltz, Leonard B ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

5 FluorouracilU; Adjuvant therapy; Colorectal cancer; Disease free survival

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; PLACEBO; UFT;

ARTERY THROMBOSIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; COLON CANCER; COLON SURGERY; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE MARKER; DRUG EFFICACY; DRUG RESPONSE; FEBRILE NEUTROPENIA; HUMAN; HYPERTENSION; MICROSATELLITE INSTABILITY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; PROGNOSIS; PROTEINURIA; RECURRENCE RISK; REVIEW; SENSORY NEUROPATHY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COLONIC NEOPLASMS; HUMANS; IMMUNOTHERAPY; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT;

EID: 77957145194     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2010.07.005     Document Type: Review

References (24)

1. Greene F., Stewart A., Norton H. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg 2002, 236:416-421.
2. Moertel C., Fleming T., Macdonald J., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990, 322:352.
3. Haller D.G., Catalano P.J., Macdonald J.S., et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 2005, 23:8671-8678.
4. Van Cutsem E., Twelves C., Cassidy J., et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001, 19:4097-4106.
5. Saltz L.B., Leichman C.G., Young C.W., et al. A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer. Cancer 1995, 75:782-785.
6. Lembersky B.C., Wieand H.S., Petrelli N.J., et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006, 24:2059-2064.
7. Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343-2351.
8. Andre T., Boni C., Navarro M., et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009, 27:3109-3116.
9. Haller D, Tabernero J, Maroun J, et al. 5LBA First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study). Proceedings of European Society of Medical Oncology (ESMO) 2009;7:4.
10. Saltz L.B., Neidzweicki D., Hollis D., et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007, 25:3456-3461.
11. Ychou M., Raoul J., Douillard J.Y., et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 2009, 20:674-680.
12. Van Cutsem E., Labianca R., Hossfeld G., et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009, 27:3117-3125.
13. Saltz L.B., Clarke S., Diaz-Rubio E., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26:2013-2019.
14. Wolmark N., Yothers G., O'Connell M.J., et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP protocol C-08 [abstract]. J Clin Oncol 2009, 27(Suppl):LBA4.
15. Alberts S.R., Sargent D.J., Smyrk C.J., et al. Adjuvant mFOLFOX6 with or without cetuximab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): results from NCCTG intergroup phase III trial N0147 [abstract]. J Clin Oncol 2010, 28(Suppl):CRA3507.
16. Moertel C.G., Fleming T.R., Macdonald J.S., et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Duke's B2 colon cancer. J Clin Oncol 1995, 13:2936-2943.
17. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007, 370:2020-2029. QUASAR Collaborative Group.
18. Aarnio M., Sankila R., Pukkala E., et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999, 81:214-218.
19. Schrag D., Rifas-Shiman S., Saltz L., et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 2002, 20:3999-4005.
20. Gill S., Loprinzi C.L., Sargent D.J., et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. J Clin Oncol 2004, 22:1797-1806.
21. Figueredo A., Charette M.L., Maroun J., et al. Adjuvant therapy for stage II colon cancer: a systematic review from the cancer care Ontario program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 2004, 22:3395-3407.
22. Benson A.B., Schrag D., Somerfield M.R., et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004, 22:3408-3419.
23. Kim G.P., Colangelo L.H., Wieand H.S., et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a national cancer institute-national surgical adjuvant breast and bowel project collaborative study. J Clin Oncol 2007, 25:767-772.
24. Sargent D.J., Marsoni S., Monges G., et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010, 28:3219-3226.